Investigating the role of plasma cells in lung transplant rejection
Role of plasma cells in chronic rejection after lung transplantation
This study is looking at how certain immune cells, called plasma cells, might play a role in lung transplant rejection, especially for patients dealing with bronchiolitis obliterans syndrome, and it hopes to find new ways to help improve the success of lung transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11181272 on NIH RePORTER |
What this research studies
This research focuses on understanding how plasma cells contribute to chronic rejection in lung transplant patients. It aims to identify specific immune cell populations involved in the rejection process, particularly in the context of bronchiolitis obliterans syndrome, a common complication after lung transplantation. By utilizing a novel mouse model and analyzing patient samples, the study seeks to uncover the mechanisms behind tissue remodeling and immune responses that lead to chronic lung allograft dysfunction. This could provide insights into potential therapeutic targets for improving transplant outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone lung transplantation and are experiencing or at risk for chronic rejection.
Not a fit: Patients who have not received a lung transplant or those with acute rejection without chronic complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing chronic rejection in lung transplant patients, enhancing their long-term survival.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in transplant rejection, suggesting that this approach could yield valuable insights.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Eickelberg, Oliver — University of Pittsburgh at Pittsburgh
- Study coordinator: Eickelberg, Oliver
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.